**Name of journal: World Journal of Gastrointestinal Oncology**

**ESPS Manuscript NO: 9771**

**Columns: CASE REPORT**

Neuroendocrine tumors of the gastrointestinal tract: Case reports and literature review

Salyers WJ *et al*. Neuroendocrine tumors of the gastrointestinal tract

William J Salyers, Kenneth J Vega, Juan Carlos Munoz, Bruce W Trotman, Silvio S Tanev

**William J Salyers, Kenneth J Vega, Juan Carlos Munoz,** Division of Gastroenterology, University of Florida College of Medicine/Jacksonville, Jacksonville, FL 32207, United States

**Kenneth J Vega,** Division of Digestive Diseases and Nutrition, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, United States

**Bruce W Trotman**, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, United States

**Silvio S Tanev,** Department of Pathology, Manatee Memorial Hospital, Bradenton, FL 34208, United States

**Author contributions:** Salyers WJ collected the data at the U of Florida College of Medicine/Jacksonville and wrote the initial manuscript; Vega KJ and Munoz JC supervised the initial manuscript; Trotman BW contributed cases; Bradenton FL and edited the manuscript; Tanev S gathered the pathology slides and prepared the slides for publication.

**Correspondence to: Kenneth J Vega, MD,** Division of Digestive Diseases and Nutrition, University of Oklahoma Health Sciences Center, 920 Stanton L Young Boulevard, WP 1345, Oklahoma City, OK 73104, United States. kenneth-vega@ouhsc.edu

**Telephone:** +1-405-2715428 **Fax:** +1-405-2715803

**Received:** February 27, 2014 **Revised:** June 7, 2014

**Accepted:** June 18, 2014

**Published online:**

**Abstract**

Neuroendocrine tumors (NET) previously called carcinoid tumors are neoplasms of enterochromaffin/neuroendocrine cell origin which display neurosecretory capacity that may result in the carcinoid syndrome. The annual incidence of patients with NET is 8.4 per 100000; yet many NET remain asymptomatic and clinically undetected. A majority of NET follows a benign course; however, some will display malignant characteristics. NET most commonly occur in the gastrointestinal tract (67%) and bronchopulmonary system (25%). Gastrointestinal NET occur within the stomach, small intestine, liver, and rectum. We report a retrospective study of 11 subjects: Eight with benign carcinoid tumors: duodenal bulb (*n =* 2), terminal ileum (*n =* 1), sigmoid colon (*n =* 2), and rectum (*n =* 3); three with malignant carcinoid: liver (*n =* 1) and intra-abdominal site (*n =* 2). The diagnosis, endoscopic images, outcome, treatment and review of the literature are presented.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words:** Neuroendocrine; Carcinoid; Gastrointestinal; Tumors

**Core tip:** Endoscopic procedures sometimes reveal submucosal lesions within the gastrointestinal tract that are resected and confirmed as neuroendocrine tumors by appropriate immunochemical stains. Most will be benign as demonstrated in our series of 11 subjects. This case series of gastrointestinal neuroendocrine tumors reminds every endoscopist to carefully examine the upper and lower gastrointestinal tract for such lesions.

Salyers WJ, Vega KJ, Munoz JC, Trotman BW, Tanev SS. Neuroendocrine tumors of the gastrointestinal tract: Case reports and literature review. *World J Gastrointest Oncol* 2014; In press

**INTRODUCTION**

Historically described as a more indolent behaving tumor than adenocarcinoma by Oberndorfer in Germany in 1907, neuroendocrine (carcinoid) tumors (NET) are undergoing a location change within the gastrointestinal tract[1-4]. A shift in the anatomic location has occurred over the last half-century. Data from 1950 to 1971 identified the appendix as the most common site followed by rectal and ileum for NET[4]. However, a recent evaluation of carcinoid tumors identified in the Surveillance, Epidemiology and End Results Program (SEER) between 1973 and 1999 found the ileum to be the most frequent site of gastrointestinal NET followed by the rectum; the appendix accounted for only 4.8% of NET[4]. Additionally, gastric NET accounted for an increasing proportion of gastrointestinal NET[4-5]. This change in location of NET has resulted from changes in diagnostic modalities used as well as reporting techniques over time[6]. The estimated incidence in the United States ranges from 2.5 - 5 cases per 100000[4]. A European investigation which included both surgical and autopsy specimens, reported an overall incidence of 8.4 cases per 100000[4, 7, 8]. Incidence estimates are limited by the clinically silent nature of many NET which remain undetected until autopsy[6].

**CASE REPORT**

This case series describes a wide spectrum of benign gastrointestinal NET originating in the small intestine (*n =* 2), terminal ileum (*n =* 1), colon (*n =* 2), rectum (*n =* 3), malignant NET of the liver (*n =* 1) and intraabdominal sites (*n =* 2) (Table 1).

***Patient 1***

A 65-year-old female with a history of possible inflammatory bowel disease presented for evaluation of epigastric pain and occasional hematochezia. Colonoscopy revealed multiple polypoid lesions throughout the colon with biopsies consistent with mucosal prolapse syndrome. Esophagogastrastroduodenoscopy (EGD) revealed mild esophagitis, chronic gastritis, and a 5 mm polyp in the duodenal bulb biopsied with cold forceps (Figure 1A). Pathology demonstrated duodenal mucosa with atypical organized nests of cells with expression of low molecular cytokeratin, neuron-specific enolase (NSE), chromogranin, and synaptophysin on immunohistochemistry consistent with a neuroendocrine tumor (Figure 1B and C). Repeat EGD was performed 35 mo later and revealed no residual neuroendocrine tumor.

***Patient 2***

A 61-year-old male with a history of gastroesophageal reflux disease (GERD) underwent EGD for evaluation of chest discomfort with breakthrough reflux symptoms while taking a proton pump inhibitor daily. LA Grade C esophagitis and ulcerated mucosa were present in the distal esophagus. A 6 mm sessile polyp also observed in the duodenal bulb and resected by snare. Pathology revealed a neuroendocrine tumor of the duodenum. PET-CT was performed and demonstrated no evidence of hypermetabolic malignancy. A repeat EGD with biopsies from the previous polypectomy site six weeks later demonsrated reactive duodenopathy with foveolar metaplasia but no residual neuroendocrine tumor.

***Patient 3***

A 50-year-old female with chronic diarrhea was found to have metastatic liver disease of unknown primary origin on computed tomography (CT). The largest lesion measured

9 cm × 6 cm in the right hepatic lobe and PET-CT demonstrated only moderate metabolic activity consistent with a neuroendocrine tumor. CT-guided liver biopsy demonstrated metastatic neuroendocrine tumor with positive synaptophysin, chromogranin, NSE, and CD57 reactions on immunohistochemistry. EGD was performed that showed chronic esophagitis, hiatal hernia, and nodularity in the gastric fundus. Pathology from gastric biopsies revealed only benign lymphoid aggregates. Follow-up CT findings included a 2.4 cm partially calcified mass in the mid-abdominal mesentery suggestive of a neuroendocrine tumor of small bowel origin. The patient was started on long-acting octreotide and entered into hospice care 28 months after initial presentation.

***Patient 4***

A 70-year-old male presenting with epigastric pain and 15 pound weight loss underwent upper endoscopy revealing chronic esophagitis, hiatal hernia, acute and chronic gastritis involving the antrum, and a small polypoid lesion which was found in the duodenal bulb. Biopsies were consistent with chronic duodenitis. Colonoscopy revealed one tubular adenoma < 1 cm and multiple hyperplastic polyps. A 3 cm mesenteric mass with surrounding desmoplastic reaction, small bowel thickening, and a 2 cm liver lesion were found on CT of the abdomen and pelvis (Figure 2 A). CT guided biopsy of the mesenteric mass demonstrated a metastatic well-differentiated neuroendocrine tumor with immunohistochemistry positive for cytokeratin, NSE, synaptophysin, chromogranin, and CD56 (Figure 2B and C); however, biopsy of the liver lesion was negative for malignancy. PET-CT demonstrated heterogenous metabolic activity of the mesenteric mass with metabolic activity of the liver lesion similar to the surrounding hepatic parenchyma. Urinary 5-hydroxyindoleacetic acid (5-HIAA) was within normal range. The overall presentation was most consistent with a neuroendocrine tumor originating in the small bowel. The patient was started on long-acting octreotide therapy and did not undergo surgical resection of the tumor.

***Patient 5***

A 45-year-old female presented to an outside facility with nausea, vomiting, and abdominal pain and had dilation of the small bowel and colon and ascitic fluid on CT scan. Gastrografin enema demonstrated an obstruction in the sigmoid colon. An area of desmoplastic reaction involving the sigmoid colon was found during exploratory laparotomy along with multiple metastatic lesions to the liver and mesenteric and peritoneal implants. Surgical decompression of the small bowel and colon was performed and the patient was transferred for further care. Biopsies obtained from the peritoneal implants were consistent with a low-grade neuroendocrine tumor with immunohistochemistry positive for chromogranin and synaptophysin. Serum chromogranin A level was elevated at 27 nmol/L. Following transfer to our facility, the patient underwent colonoscopy which revealed a 3cm area of stenosis due to extrinsic compression 30cm from the anal verge. As no further surgical intervention was deemed appropriate, two overlapping metal colonic stents (Wallstent, 22 mm × 90 mm and 22 mm × 60mm) were placed across the area of stenosis. The patient was later discharged for hospice care.

***Patient 6***

A 40-year-old male with recurrent perianal fistulous disease underwent colonoscopy to rule out inflammatory bowel disease. Colonoscopy revealed normal colonic mucosa and a 1 cm sessile polyp at the terminal ileum (Figure 3A). Snare polypectomy was performed and pathology revealed a submucosal neuroendocrine tumor with well formed nests of cells and diffuse expression of synaptophysin and chromogranin. KI-67 proliferative index was < 5% **(**Figure 3B and C). The patient was lost to follow-up.

***Patient 7***

A 50-year-old female presented for evaluation of GERD and colon cancer screening. EGD revealed a hiatal hernia, chronic esophagitis, and chronic gastritis. On colonoscopy, benign polyps were removed from the cecum and transverse colon. A 5 mm sessile polyp resected with hot forceps in the sigmoid colon (Figure 4A); pathology demonstrated atypical proliferation of cells and glandular-like inflammation with monotonous nuclei indicative of a neuroendocrine tumor. Immunostains were positive for chromogranin, synaptophysin, and CD56 consistent with a neuroendocrine tumor (Figure 4B and C). Somatostatin receptor scintigraphy demonstrated no evidence of other carcinoid tumors. Surveillance colonoscopy performed one year later revealed a scar at the site of the previously resected tumor without tumor recurrence.

***Patient 8***

A 77-year-old female with Stage I right breast cancer presented for screening colonoscopy. A 7 mm submucosal nodule was biopsied from the sigmoid colon; pathology revealed tumor cells positive for synaptophysin and negative for chromogranin but overall consistent with a neuroendocrine tumor. Urinary 5-HIAA levels and octeotride scan were unremarkable. Endoscopic mucosal resection (EMR) was subsequently performed with a snare. Excisional biopsy consisted of a 7 mm × 6 × mm × 3 mm submucosal neuroendocrine tumor. Colonoscopy one year later revealed no recurrence.

***Patient 9***

A 55-year-old male presented for evaluation of left lower quadrant tenderness and colon cancer screening. Colonoscopy revealed a 1.4 cm tubulovillous adenoma in the sigmoid colon. A 6 mm rectal polyp removed by snare was consistent with a neuroendocrine tumor. Surveillance colonoscopy three years later revealed a 6 mm hyperplastic polyp in the rectum and no evidence of recurrence of a neuroendocrine tumor.

***Patient 10***

A 54-year-old female presented for colon cancer screening. On colonoscopy, an 8 mm nodule was found in the rectum. Snare polypectomy was performed. Pathology demonstrated atypical proliferation of cells and glandular-like inflammation with monotonous nuclei suggestive of a neuroendocrine tumor. Colonoscopy one year later was negative for recurrence.

***Patient 11***

A 60-year-old female presented for colon cancer screening. On colonoscopy, a 5 mm submucosal nodule was found in the rectum and removed snare polypectomy. The biopsy was consistent with a neuroendocrine tumor involving the submucosa with tumor cells positive for synaptophysin and focally positive for chromogranin. Fourteen months later, colonoscopic biopsies from the polypectomy site revealed no recurrence.

**DISCUSSION**

Our case series describes a wide spectrum of benign gastrointestinal NET originating in the small intestine, colon, and rectum and malignant NET originating in the liver and intraabdominal sites. The following discussion will focus on the diagnosis and management of NET originating from the luminal gastrointestinal tract and will not include pancreatic NET.

Advances in our understanding of both the biologic and morphologic heterogeneity of NET have left the term “carcinoid” nearly obsolete[7]. Gastroenteropancreatic neuroendocrine tumors (GEP-NET), encompassing both traditional gastrointestinal carcinoids and pancreatic endocrine tumors, are replacing the less descriptive and often times pathologically and clinically more confusing term “carcinoid”[3, 9]. In 2000, the World Health Organization (WHO) classification replaced “carcinoid” with the terms neuroendocrine tumors and neuroendocrine carcinomas to describe gastrointestinal neoplasms originating from the diffuse system of neuroendocrine cells[9]. Along with developing TNM staging and grading systems[10-14], the WHO classification[9] provides an improved system for determining prognosis and treatment and includes three main groups subdivided by organ of tumor origin: (1) well differentiated neuroendocrine tumors (benign behavior or uncertain malignant potential – “carcinoids”); (2) well differentiated neuroendocrine carcinomas (low-grade malignancy – “malignant carcinoids”); and (3) poorly-differentiated carcinomas (high-grade malignancy). This classification replaces the previous outdated system which was based on embryologic cell of origin (foregut, midgut, hindgut) and shared little correlation between tumor behavior and tumor location especially for neoplasms originating in the foregut (tracheobronchopulmonary, gastric, and pancreatic tumors)[3, 9]. Histologically, tumor proliferation capacity is measured by Ki-67 staining with Ki-67 Index < 2% seen in grade I tumors, 2%-20% in grade II tumors, and > 20% tumor cell involvement in grade III GEP-NET[11].

Cells originating from the diffuse system of neuroendocrine cells within the gastrointestinal tract share phenotypic similarities with neural cells in their expression of synaptophysin, NSE, and chromogranin A[3, 10]. Useful as GEP-NET markers found on the secretory vesicles of neuroendocrine cells, these proteins usually remain independent of cellular production of hormones that are stored within the vesicles[3, 10, 15]. Hormone production and biologic activity generally varies by GEP-NET location (Table 2) and less than half of the known hormones originating from at least 15 different types of endocrine cells are expressed by GEP-NET[15]. Many tumors remain clinically silent and may present with intestinal obstruction as a result of tumor-induced fibrosis rather than signs or symptoms of secretory products[3]. The classic carcinoid syndrome (cutaneous flushing and secretory diarrhea) occurs in less than 10% of patients[3] and typically in the setting of hepatic metastases.

***Diagnostic evaluation***

Initial evaluation of patients with a suspected GEP-NET should include a serum chromogranin A level[3, 16]. Elevated in approximately 80% of patients with neuroendocrine tumors regardless of location and functional activity, chromogranin A levels also appear to correlate with overall tumor burden[17]. Twenty-four-hour urinary 5-HIAA levels as well as serum gastrin, histamine, serotonin, and substance P levels should be included as part of the initial evaluation when the presentation is consistent with carcinoid syndrome[3].Urinary 5-HIAA elevation sensitivity is as high as 100% with a specificity of 88% for the carcinoid syndrome[18].Care must be taken to avoid medications and foods that may affect urinary 5-HIAA excretion; large amounts of serotonin are in foods as avocados, bananas, eggplant, kiwi, pineapple, plums, tomatoes, and walnuts and may cause false positive results[16].

Patients with positive biochemical markers should be evaluated with somatostatin receptor scintigraphy (111Indium-labeled octreotide scan) for tumor localization as well as either computed tomography (CT) or magnetic resonance imaging (MRI) to identify mass lesions, mesenteric fibrosis, and lymphadenopathy[3, 16]. 111Indium-labeled octreotide scan is useful in detection of both primary and metastatic tumors with sensitivity as high as 90%[3, 19]. CT and MRI play an important role in identification of primary tumors and metastatic disease; however, they may underestimate the extent of disease in up to 25% of cases[20, 21]and overall sensitivities around 80% are lower than 111Indium-labeled octreotide scanning[3]. Radiolabeled metaiodobenzylguanide (123I-MIBG) scanning may be used in patients on long-acting octreotide medications which interfere with somatostatin receptor scintigraphy[3]. Radiolabeled 5-HTP positron emission tomography has demonstrated better sensitivities than CT and octreotide scanning; however, it is not widely available and is generally still considered an investigational modality[3, 21, 22]. Barium studies, including small-bowel-follow-through, play little if any role in tumor localization with the availability of other diagnostic modalities with increased sensitivity[23].

Following tumor localization, biopsy for tissue diagnosis should be obtained including performing upper endoscopy and colonoscopy with ileoscopy as clinically indicated[3, 16]. Small bowel enteroscopy has low diagnostic sensitivities as well as a limited ability to evaluate the distal jejunum and ileum and has largely been replaced by capsule endoscopy in both diagnostic and surveillance roles[3,24, 25]. Endoscopic ultrasound (EUS) plays in important role in guiding management as it is accurate in assessing tumor size and depth of invasion especially in gastric, duodenal, and rectal carcinoid tumors[26, 27].

***Site specific information***

Gastric carcinoids are typically divided into Type I, II, and III tumors with some classifications including Type IV tumors[9]. Type I and II gastric carcinoid tumors develop in response to hypergastrinemia effects on enterochromaffin-like cells of the oxyntic mucosa found in the gastric fundus and body[28-30]. Type I are the most common gastric NET tumors usually presenting as small multifocal lesions associated with autoimmune chronic atrophic gastritis and hypergastrinemia in the setting of low gastric acid output[3, 9, 30].They have an excellent prognosis with 5-year survival rates > 95%[3]. Type II gastric NET develop in patients with Multiple Endocrine Neoplasia type-1 (MEN-1) associated Zollinger-Ellison syndrome (ZES) as a result of tumor driven hypergastrinemia in the setting of an autosomal dominant mutation of the MEN-1 gene located on chromosome 11q13[9, 29, 30]. Type II gastric NET rarely develop in patients with sporadic ZES[29]. Prognosis is good with 5-year survival rates of 70%–90%[3].

Type I and II tumors < 1 cm in size without extension into the muscularis propria on EUS can initially be managed with endoscopic mucosal resection[3, 26, 31]. When more than 5 lesions are present, tumor size is > 1 cm, or recurrence occurs at a site of previous endoscopic resection, local surgical excision is recommended[3]. Type II lesions may require aggressive gastrectomy as well as surgical resection of the underlying gastrinoma[3]. Surveillance endoscopy with biopsy should be performed every six months following both endoscopic and surgical tumor removal[3].

Type III tumors are sporadic gastric carcinoids which develop in normal gastric mucosa in the setting of normal gastrin levels[3, 9]. They are aggressive with deep invasion and the potential for metastatic disease characteristic of even small primary tumors[26]. Five-year survival rates are < 35%[3]. Type IV tumors are neuroendocrine carcinomas which are indistinguishable from gastric adenocarcinomas with the exception of the presence of neuroendocrine cells within the tumor matrix[3]. Both type III and IV tumors should be managed surgically with complete or partial gastrectomy[3 ,9].

***Small intestine***

**Duodenal**: Five types of duodenal neuroendocrine tumors have been described[32]: (1) gastrinomas which may occur sporadically or in the setting of MEN-1/ZES and are the most common duodenal NET[3, 9, 32]; (2) somatostatinomas which usually occur in the ampullary/periampullary region and are more likely to be associated with von Recklinghausen’s disease (neurofibromatosis type 1) [3, 33]; (3) gangliocytic paraganglionomas[3, 9, 32]; (4) nonfunctioning NET which contain serotonin-, gastrin-, or calcitonin-positive cells[3, 9]; and (5) neuroendocrine carcinomas[3, 32, 33]. Overall 5-year survival for duodenal carcinoid lesions is 60%[3]. Endoscopic resection may be considered for nonmetastatic duodenal (and ampullary) lesions measuring up to 2 cm if the tumor is confined to the mucosa and submucosa on EUS examination[3, 33-35]. Surgical resection should be performed on tumors > 2 cm[34, 35]. While distant metastases rarely occurs with duodenal NET, lymph node metastases may occur in tumors < 1 cm and surgical resection should be performed in all patients with evidence of lymph node involvement on pretreatment imaging studies[35].

**Jejuno-Ileal:** Terminal ileum NET are the most common GEP-NET. They are frequently found at an advanced stage with metastatic disease to the liver present in 50% and regional lymph node involvement in up to 70% of patients regardless of primary tumor size[21]. Associated mesenteric fibrosis, nodal metastases, and desmoplastic reactions involving mesenteric vessels may lead to nonspecific abdominal pain, gastrointestinal bleeding, intermittent ischemia, or bowel obstruction. These symptoms may prompt emergent surgical intervention and subsequent diagnosis of a previously unidentified jejunal or ileal NET in up to 40% of patients[3, 21]. Ileal NET are associated with the carcinoid syndrome in the setting of liver metastases in approximately 20% of cases[9, 21]. While the 5-year survival rate is 60% for both jejunal and ileal tumors, it is as low as 18% when hepatic metastases are present[3]. Surgical resection of the primary tumor as well as en bloc resection of regional lymph nodes is recommended and should be performed even when hepatic metastases is present in order to delay progression and local complications of disease[21, 31].

**Appendix:** Appendiceal NET are the most common appendiceal tumor[21]. They are often found incidentally during appendectomy with the majority (90%) of tumors < 1 cm in size. Overall 5-yr survival for appendiceal NETs is 98% for benign tumors and 27% for malignant tumors[3]. Metastatic disease rarely occurs with tumors < 2 cm and the occurrence of metastases increases with increasing tumor size over 2 cm[3, 21, 36]. Tumors > 2 cm should be managed with right hemicolectomy. Appendectomy should be performed in tumors < 2 cm in size with right hemicolectomy considered for tumors 1-2 cm based on pathologic criteria (invasion into mesoappendix, serosal or lymphovascular invasion, involvement of tumor margins, positive lymph nodes, or Ki67 index > 2% on immunohistochemistry staining)[21]. Variant mixed endocrine/exocrine goblet-cell (adenocarcinoid) tumors are more aggressive lesions associated with a poorer prognosis and higher rates of both metastastatic and recurrent disease and should be managed with right hemicolectomy regardless of tumor size[21, 36].

**Colon:** Neuroendocrine tumors rarely occur in the colon with many previously reported cecal NET representing appendiceal tumors[3, 9]. Clinical presentation of colonic NET includes change in bowel habits, gastrointestinal bleeding, abdominal pain, weight loss, and asymptomatic lesions found during screening colonoscopy is generally indistinguishable from other mass lesions of the colon[3, 9]. Most tumors are > 2cm in size with invasion into the muscularis propria at the time of diagnosis and overall prognosis is poor with 5-year survival rates of only 33%-42%[3]. Wide surgical resection with lymph node dissection is recommended for management of colonic NET[3]as metastatic disease is common at the time of diagnosis[9]. Local excision may be considered for tumors < 2 cm in size[3]; however, data regarding metastatic disease in this setting are limited.

**Rectum:** Frequently found as small, asymptomatic submucosal tumors during endoscopic evaluation, rectal NET have an excellent overall prognosis with 5-year survival rates of 87%[3, 9]. When present, symptoms may include change in bowel habits, gastrointestinal bleeding, anorectal discomfort, and pruritis ani[3]. Submucosal tumors < 1 cm in size account for 80% of rectal carcinoids[3] and can be managed endoscopically in the absence of muscularis invasion or pararectal lymph node metastases on EUS examination[31, 37]. Rectal NETs 1-2 cm in size may be managed with wide surgical excision if there is no evidence of muscularis invasion or lymph node metastasis[3]. Low anterior resection or abdominoperineal resection is recommended for tumors > 2 cm as the risk of metastatic disease increases with tumors > 2 cm in size and with invasion of the muscularis propria[3, 9].

***Medical therapy***

Following surgical resection of a GEP-NET, medical therapy may be required for symptom management related to functional tumor syndromes as well as management of progressive metastatic and residual disease[31, 38, 39]. Patients with symptomatic functional NET should be considered for somatostatin (SST) analog (short- or long-acting octreotide) or interferon- α therapy alone or in combination[3, 31, 38, 39]. In addition to reducing symptoms in patients with carcinoid syndrome[40, 41], VIPoma associated Verner-Morrison syndrome (watery diarrhea, hypokalemia, and achlorhydria)[40, 42], and glucagonoma associated necrolytic migratory erythema[4], SST analogs may also play a role in growth inhibition of nonfunctioning NET[39, 41]. Interferon-α therapy may be considered in patients who become intolerant or resistant to SST analog therapy as it has also been shown to reduce diarrhea and flushing in patients with carcinoid syndrome[39].

Systemic chemotherapy or peptide receptor radionuclide therapy with I-131 MIBG, Yttrium90, or Lutetium177 should be considered in patients with metastatic disease with tansarterial embolization/chemoembolization or radiofrequency ablation considered when metastases are limited to the liver[3, 31, 38, 39].

Patients undergoing biologic or cytotoxic therapies should have their clinical response to treatment monitored every 3 mo[11]. Biochemical markers (based on the functional status of their underlying tumor) should be followed every 3-6 mo along with CT or MRI scanning every 6 mo for 5 years following curative surgical resection[11].

In a conclusion, GEP-NET are relatively rare neoplasms of the gastrointestinal tract with variable clinical presentation, morbidity, and mortality dependent on tumor location, metastatic potential, and functional biologic status. Staging and classification systems for GEP-NET are likely to continue to evolve along with further development of tumor directed diagnostic and therapeutic modalities as our understanding of GEP-NET continues to expand over time.

**COMMENTS**

***Case characteristics***

This case series describes a wide spectrum of benign gastrointestinal neuroendocrine (carcinoid) tumors.

***Clinical diagnosis***

the diagnosis and management of neuroendocrine tumors (NET) originating from the luminal gastrointestinal tract and will not include pancreatic NET.

***Imaging diagnosis***

Computed tomography and magnetic resonance imaging play an important role in identification of primary tumors and metastatic disease.

***Experiences and lessons***

GEP-NET are relatively rare neoplasms of the gastrointestinal tract with variable clinical presentation, morbidity, and mortality dependent on tumor location, metastatic potential, and functional biologic status.

***Peer review***

The diagnosis and management of NET originating from the luminal gastrointestinal tract and will not include pancreatic NET

**REFERENCES**

1 **Klöppel G**. Oberndorfer and his successors: from carcinoid to neuroendocrine carcinoma. *Endocr Pathol* 2007; **18**: 141-144 [PMID: 17960501 DOI: 10.1007/s12022-007-0021-9]

2 **Oberndorfer S**. Karzinoide Tumoren des Dunndarms. *Frank Z Pathol* 1907; **1**: 426-429

3 **Modlin IM**, Kidd M, Latich I, Zikusoka MN, Shapiro MD. Current status of gastrointestinal carcinoids. *Gastroenterology* 2005; **128**: 1717-1751 [PMID: 15887161 DOI: 10.1053/j.gastro.2005.03.038]

4 **Modlin IM**, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. *Cancer* 2003; **97**: 934-959 [PMID: 12569593 DOI: 10.1002/cncr.11105]

5 **Modlin IM**, Lye KD, Kidd M. A 50-year analysis of 562 gastric carcinoids: small tumor or larger problem? *Am J Gastroenterol* 2004; **99**: 23-32 [PMID: 14687136 DOI: 10.1046/j.1572-0241.2003.04027.x]

6 **Kulke MH**, Mayer RJ. Carcinoid tumors. *N Engl J Med* 1999; **340**: 858-868 [PMID: 10080850 DOI: 10.1056/NEJM199903183401107]

7 **Modlin IM**, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP, Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P, Sundin A. Gastroenteropancreatic neuroendocrine tumours. *Lancet Oncol* 2008; **9**: 61-72 [PMID: 18177818 DOI: 10.1016/S1470-2045(07)70410-2]

8 **Berge T**, Linell F. Carcinoid tumours. Frequency in a defined population during a 12-year period. *Acta Pathol Microbiol Scand A* 1976; **84**: 322-330 [PMID: 961424]

9 **Klöppel G**, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. *Ann N Y Acad Sci* 2004; **1014**: 13-27 [PMID: 15153416 DOI: 10.1196/annals.1294.002]

10 **Klöppel G**, Couvelard A, Perren A, Komminoth P, McNicol AM, Nilsson O, Scarpa A, Scoazec JY, Wiedenmann B, Papotti M, Rindi G, Plöckinger U. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. *Neuroendocrinology* 2009; **90**: 162-166 [PMID: 19060454 DOI: 10.1159/000182186]

11 **Oberg K**, Jelic S. Neuroendocrine gastroenteropancreatic tumors: ESMO clinical recommendation for diagnosis, treatment and follow-up. *Ann Oncol* 2009; **20** Suppl 4: 150-153 [PMID: 19454440 DOI: 10.1093/annonc/mdp158]

12 **Pape UF**, Jann H, Müller-Nordhorn J, Bockelbrink A, Berndt U, Willich SN, Koch M, Röcken C, Rindi G, Wiedenmann B. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. *Cancer* 2008; **113**: 256-265 [PMID: 18506737 DOI: 10.1002/cncr.23549]

13 **Rindi G**, Klöppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, Erikssson B, Falchetti A, Falconi M, Komminoth P, Körner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. *Virchows Arch* 2006; **449**: 395-401 [PMID: 16967267 DOI: 10.1007/s00428-006-0250-1]

14 **Rindi G**, Klöppel G, Couvelard A, Komminoth P, Körner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. *Virchows Arch* 2007; **451**: 757-762 [PMID: 17674042 DOI: 10.1007/s00428-007-0452-1]

15 **Ardill JE**. Circulating markers for endocrine tumours of the gastroenteropancreatic tract. *Ann Clin Biochem* 2008; **45**: 539-559 [PMID: 18941127 DOI: 10.1258/acb.2008.008039]

16 **Ghevariya V**, Malieckal A, Ghevariya N, Mazumder M, Anand S. Carcinoid tumors of the gastrointestinal tract. *South Med J* 2009; **102**: 1032-1040 [PMID: 19738517 DOI: 10.1097/SMJ.0b013e3181b67356]

17 **Stivanello M**, Berruti A, Torta M, Termine A, Tampellini M, Gorzegno G, Angeli A, Dogliotti L. Circulating chromogranin A in the assessment of patients with neuroendocrine tumours. A single institution experience. *Ann Oncol* 2001; **12** Suppl 2: S73-S77 [PMID: 11762356 DOI: 10.1093/annonc/12.suppl\_2.S73]

18 **Tormey WP**, FitzGerald RJ. The clinical and laboratory correlates of an increased urinary 5-hydroxyindoleacetic acid. *Postgrad Med J* 1995; **71**: 542-545 [PMID: 7479466 DOI: 10.1136/pgmj.71.839.542]

19 **Kwekkeboom DJ**, Kam BL, van Essen M, Teunissen JJ, van Eijck CH, Valkema R, de Jong M, de Herder WW, Krenning EP. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. *Endocr Relat Cancer* 2010; **17**: R53-R73 [PMID: 19995807 DOI: 10.1677/ERC-09-0078]

20 **Chambers AP**, Pasieka JL, Dixon E, Rorstad O. The role of imaging studies in the staging of midgut neuroendocrine tumors. *J Am Coll Surg* 2009; **207**: S18. doi: 10.1016/j.jamcollsurg.2008.06.021

21 **Pasieka JL**. Carcinoid tumors. *Surg Clin North Am* 2009; **89**: 1123-1137 [PMID: 19836488 DOI: 10.1016/j.suc.2009.06.008]

22 **Orlefors H**, Sundin A, Garske U, Juhlin C, Oberg K, Skogseid B, Langstrom B, Bergstrom M, Eriksson B. Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. *J Clin Endocrinol Metab* 2005; **90**: 3392-3400 [PMID: 15755858 DOI: 10.1210/jc.2004-1938]

23 **Sippel RS**, Chen H. Carcinoid tumors. *Surg Oncol Clin N Am* 2006; **15**: 463-478 [PMID: 16882492 DOI: 10.1016/j.soc.2006.05.002]

24 **Bellutti M**, Fry LC, Schmitt J, Seemann M, Klose S, Malfertheiner P, Mönkemüller K. Detection of neuroendocrine tumors of the small bowel by double balloon enteroscopy. *Dig Dis Sci* 2009; **54**: 1050-1058 [PMID: 18770038 DOI: 10.1007/s10620-008-0456-y]

25 **Coates SW**, DeMarco DC. Metastatic carcinoid tumor discovered by capsule endoscopy and not detected by esophagogastroduodenoscopy. *Dig Dis Sci* 2004; **49**: 639-641 [PMID: 15185871 DOI: 10.1023/B: DDAS.0000026311.62364.0b]

26 **Ichikawa J**, Tanabe S, Koizumi W, Kida Y, Imaizumi H, Kida M, Saigenji K, Mitomi H. Endoscopic mucosal resection in the management of gastric carcinoid tumors. *Endoscopy* 2003; **35**: 203-206 [PMID: 12584637 DOI: 10.1055/s-2003-37256]

27 **Ishii N**, Horiki N, Itoh T, Maruyama M, Matsuda M, Setoyama T, Suzuki S, Uchida S, Uemura M, Iizuka Y, Fukuda K, Suzuki K, Fujita Y. Endoscopic submucosal dissection and preoperative assessment with endoscopic ultrasonography for the treatment of rectal carcinoid tumors. *Surg Endosc* 2010; **24**: 1413-1419 [PMID: 20033710 DOI: 10.1007/s00464-009-0791-x]

28 **Borch K**, Ahrén B, Ahlman H, Falkmer S, Granérus G, Grimelius L. Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. *Ann Surg* 2005; **242**: 64-73 [PMID: 15973103 DOI: 10.1097/01.sla.0000167862.52309.7d]

29 **Delle Fave G**, Capurso G, Milione M, Panzuto F. Endocrine tumours of the stomach. *Best Pract Res Clin Gastroenterol* 2005; **19**: 659-673 [PMID: 16253892 DOI: 10.1016/j.bpg.2005.05.002]

30 **von Rosenvinge EC**, Wank SA, Lim RM. Gastric masses in multiple endocrine neoplasia type I-associated Zollinger-Ellison syndrome. *Gastroenterology* 2009; **137**: 1222, 537 [PMID: 19723598 DOI: 10.1053/j.gastro.2009.03.050]

31 **Ramage JK**, Davies AH, Ardill J, Bax N, Caplin M, Grossman A, Hawkins R, McNicol AM, Reed N, Sutton R, Thakker R, Aylwin S, Breen D, Britton K, Buchanan K, Corrie P, Gillams A, Lewington V, McCance D, Meeran K, Watkinson A. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. *Gut* 2005; **54 Suppl 4**: iv1-i16 [PMID: 15888809]

32 **Bordi C**, D'Adda T, Azzoni C, Canavese G, Brandi ML. Gastrointestinal endocrine tumors: recent developments. *Endocr Pathol* 1998; **9**: 99–115 10.1007/BF02782603

33 **Makhlouf HR**, Burke AP, Sobin LH. Carcinoid tumors of the ampulla of Vater: a comparison with duodenal carcinoid tumors. *Cancer* 1999; **85**: 1241-1249 [PMID: 10189128 DOI: 10.1002/(SICI)1097-0142(19990315)85: 6<1241: : AID-CNCR5>3.0.CO; 2-4]

34 **Chou JW**, Huang WH, Lai HC. A case with duodenal bleeding. *Gastroenterology* 2009; **137**: e1-e2 [PMID: 19490955 DOI: 10.1053/j.gastro.2008.12.035]

35 **Mullen JT**, Wang H, Yao JC, Lee JH, Perrier ND, Pisters PW, Lee JE, Evans DB. Carcinoid tumors of the duodenum. *Surgery* 2005; **138**: 971-97; discussion 971-97; [PMID: 16360380 DOI: 10.1016/j.surg.2005.09.016]

36 **Bamboat ZM**, Berger DL. Is right hemicolectomy for 2.0-cm appendiceal carcinoids justified? *Arch Surg* 2006; **141**: 349-52; discussion 352 [PMID: 16618891 DOI: 10.1001/archsurg.141.4.349]

37 **Onozato Y**, Kakizaki S, Iizuka H, Sohara N, Mori M, Itoh H. Endoscopic treatment of rectal carcinoid tumors. *Dis Colon Rectum* 2010; **53**: 169-176 [PMID: 20087092 DOI: 10.1007/DCR.0b013e3181b9db7b]

38 **Oberg K**, Astrup L, Eriksson B, Falkmer SE, Falkmer UG, Gustafsen J, Haglund C, Knigge U, Vatn MH, Välimäki M. Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part I-general overview. *Acta Oncol* 2004; **43**: 617-625 [PMID: 15545182 DOI: 10.1080/02841860410018575]

39 **Srirajaskanthan R**, Toumpanakis C, Meyer T, Caplin ME. Review article: future therapies for management of metastatic gastroenteropancreatic neuroendocrine tumours. *Aliment Pharmacol Ther* 2009; **29**: 1143-1154 [PMID: 19298583 DOI: 10.1111/j.1365-2036.2009.03988.x]

40 **Arnold R**, Trautmann ME, Creutzfeldt W, Benning R, Benning M, Neuhaus C, Jürgensen R, Stein K, Schäfer H, Bruns C, Dennler HJ. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. *Gut* 1996; **38**: 430-438 [PMID: 8675099 DOI: 10.1136/gut.38.3.430]

41 **Oberg K**, Kvols L, Caplin M, Delle Fave G, de Herder W, Rindi G, Ruszniewski P, Woltering EA, Wiedenmann B. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. *Ann Oncol* 2004; **15**: 966-973 [PMID: 15151956 DOI: 10.1093/annonc/mdh216]

42 **Ghaferi AA**, Chojnacki KA, Long WD, Cameron JL, Yeo CJ. Pancreatic VIPomas: subject review and one institutional experience. *J Gastrointest Surg* 2008; **12**: 382-393 [PMID: 17510774 DOI: 10.1007/s11605-007-0177-0]

43 **Massironi S**, Sciola V, Peracchi M, Ciafardini C, Spampatti MP, Conte D. Neuroendocrine tumors of the gastro-entero-pancreatic system. *World J Gastroenterol* 2008; **14**: 5377-5384 [PMID: 18803349 DOI: 10.3748/wjg.14.5377]

**P-Reviewers:** AlbuquerqueA, Anadol Z, Hasanein P  **S-Editor:** Wen LL  **L-Editor:**  **E-Editor:**

Figure 1A



Figure 1B





Figure 1C



**Figure 1 A 65-year-old female with a history of possible inflammatory bowel disease presented for evaluation of epigastric pain and occasional hematochezia.** A: Patient 1, neuroendocrine (carcinoid) tumors as duodenal nodule at endoscopy; B: Solid growth pattern with organoid architecture and bland monotonous cells with lack ofsignificant atypia and increased mitoses. H and E, × 10; C: Neoplastic neuroendocrine cells show diffuse positivity for Chromogranin. Chromogranin, ×20.

Figure 2A



Figure 2B





Figure 2C



**Figure 2 A 70-year-old male presenting with epigastric pain and 15 pound weight loss underwent upper endoscopy revealing chronic esophagitis, hiatal hernia, acute and chronic gastritis involving the antrum, and a small polypoid lesion which was found in the duodenal bulb.** A: Patient 4, neuroendocrine (carcinoid) tumors as solid spiculated mesenteric mass on computed tomography of abdomen; B: Diffuse infiltration by monotonous bland cells with trabecular growth pattern. Mitoses, atypia and necrosis are not identified. Hand E, ×10; C: The tumor cells are diffusely and strongly positive for CD56 immunohistochemical stain. CD56, × 20.

Figure 3A




Figure 3B





Figure 3C



**Figure 3 A 40-year-old male with recurrent perianal fistulous disease underwent colonoscopy to rule out inflammatory bowel disease.** A: Patient 6, neuroendocrine (carcinoid) tumors as 10 mm ileocecal sessile polyp at colonoscopy; B: Nests of monotonous cells with bland nuclei arranged in organoid pattern. H and E, ×10; C: Carcinoid tumor: Chromogranin A: Marked cytoplasmic positivity.

Figure 4A




Figure 4B





Figure 4C



**Figure 4 A 50-year-old female presented for evaluation of gastroesophageal reflux disease and colon cancer screening.** A: Patient 7, neuroendocrine (carcinoid) tumors as sessile sigmoid polyp at colonoscopy; B: Organoid growth pattern with regular bland nuclei with indistinct cell borders. H and E, ×10; C: The neuroendocrine cells are positive for Synaptophysin and adjacent colonic glands are negative. Synaptophysin, ×20.

**Table 1 Clinical data of patients with neuroendocrine tumors**

|  |
| --- |
|  |

**Patient Initial evaluation Site Diagnostic studies Outcome**

**(age/sex)**

|  |
| --- |
|  |

65F Hematochezia, IBD Duodenal 12 21 05 EGD duodenal bulb polyp; Alive and well

epigastric pain bulb Path: neuroendocrine tumor

12 30 05 repeat EGD, no residual

Path: neuroendocrine tumor

11 24 08 repeat EGD no recurrence,

COL mucosal prolapse syndrome

59M GERD with break- Duodenal 11 11 08 EGD duodenal bulb polyp, Alive and well

through symptoms bulb Path; neuroendocrine tumor

12 22 08 EGD, no residual tumor

12 30 08 PET scan negative

50F 2nd opinion for liver Liver 02 09 04 EGD chronic esophagitis, Expired 12 04

metastatic disease HH, fundic nodularity

Path: benign lymphoid aggregates

03 16 04 PET/CT innumberable large

hepatic lesions replacing R and L lobes

consistent with neuroendocrine tumor

70M Epigastric pain and Intra- 04 15 08 EGD chronic esophagitis, 05 08 treated

15 lb weight loss Abdominal HH, acute and chronic gastritis; w sandostatin

Path: reactive gastropathy;

COL: 1 adenomatous/ 2 hyperplastic

polyps; 04 16 08 CT Abd/Pelvis mesen-

teric mass; 04 24 08 CT guided bx:

Path: neuroendocrine tumor

46F Nausea, vomiting, Intra- 01 02 10 CT Abd/Pelvis ascites, Discharge

abdominal pain Abdominal small bowel and colonic obstruction To hospice

01 04 10 Gastrografin emema sigmoid

Obstruction

01 04 10 Exploratory laparotomy

desmoplastic reaction, Sigmoid colon

with liver metastases and intraperitoneal

implants; bx of implants positive for

chromogranin and synapotophysin

01 19 10 COL 3 cm stenosis at 30 cm due

to extrinsic pressure; stent placed

01 26 10 serum CGA, 27 nmole/L

40M Recurrent perianal Terminal 12 05 06 COL 10 mm sessile polyp Lost to

abcess r/o IBD Ileum in terminal ileum, Follow-up Path: neuroendocrine tumor

50F GERD and CRCS sigmoid 04 04 08 EGD chronic esophagitis, HH alive and

Path: mild reactive gastropathy well

COL 4 mm sigmoid neuroendocrine

tumor resected

04 30 08 normal octreotide scan

03 30 09 COL negative bx at prior

polypectomy site

75F Breast cancer and sigmoid 02 06 08 COL 7 mm sigmoid alive and well

CRCS submucosal nodule resected; cells

positive for synaptophysin, but

negative for chromogranin

03 11 08 Urinary 5-HIAA negative

04 22 08 Repeat COL with resection

of remaining neuroendocrine tumor

05 19 09 COL negative for recurrence

55M LLQ tenderness, rectum 08 22 06 COL sigmoid tubulovillous alive and well

CRCS adenoma and 6 mm rectal neuro-

endocrine tumor 09 01 09 COL hyperplastic polyp, no

recurrence of neuroendocrine tumor

55F CRCS rectum 05 01 09 COL 8 mm neuroendocrine alive and well

tumor COL 1 year later no recurrence

60F CRCS rectum 11 29 07 COL submucosal nodule alive and well

neuroendocrine tumor

01 28 08 COL no recurrence

|  |
| --- |
|  |

IBD: Inflammatory bowel disease; CGA: Chromogranin A; EGD: Esophagoduodenoscopy; COL: Colonoscopy; GERD: Gastroesophageal reflux disease; HH: Hiatal hernia; R: Right; L: Left; bx: Biopsy; CRCS: Colorectal cancer screening.

**Table 2 Hormone production by tumor location[15, 9, 31, 43]**

|  |  |
| --- | --- |
| **Location** | **Hormones** |
| Stomach | Histamine, Gastrin, Serotonin, Somatostatin, Gastrin Releasing Peptide |
| Duodenum/Upper Jejunum | Gastrin, Serotonin, Somatostatin, Gastrin Releasing Peptide |
| Ileum/Cecum | Enteroglucagon, Serotonin, Substance P, Tachykinins |
| Appendix | Enteroglucagon, Peptide YY, Serotonin, Somatostatin |
| Colon/Rectum | Enteroglucagon, Serotonin, Somatostatin |
| Pancreas | ACTH, Calcitonin, Cholecystokinin, Corticotropin-Releasing Hormone, Gastrin, Glucagon, Growth Hormone-Releasing Hormone, Growth Hormone-Releasing Factor, Insulin, Neurotensin, Pancreatic Polypeptide, Parathyroid Hormone-Related Peptide, Prolactin, Somatostatin, Vasoactive Intestinal Peptide |